Scholars just solved a 130-year literary mystery—and it all hinged on one word

A medieval literary puzzle which has stumped scholars including M.R. James for 130 years has finally been solved. Cambridge scholars now believe the Song of Wade, a long lost treasure of English culture, was a chivalric romance not a monster-filled epic. The discovery solves the most famous mystery in Chaucer’s writings and provides rare evidence of a medieval preacher referencing pop culture in a sermon.

The breakthrough, detailed on July 15 in The Review of English Studies, involved working out that the manuscript refers to ‘wolves’ not ‘elves’, as scholars previously assumed.

Dr James Wade and Dr Seb Falk, colleagues at Girton College, Cambridge, argue that the only surviving fragment of the Song of Wade, first discovered by M.R. James in Cambridge in 1896, has been “radically misunderstood” for the last 130 years.

“Changing elves to wolves makes a massive difference,” Seb Falk said. “It shifts this legend away from monsters and giants into the human battles of chivalric rivals.”

James Wade said: “It wasn’t clear why Chaucer mentioned Wade in the context of courtly intrigue. Our discovery makes much more sense of this.”

“Here we have a late-12th-century sermon deploying a meme from the hit romantic story of the day,” Seb Falk said. “This is very early evidence of a preacher weaving pop culture into a sermon to keep his audience hooked.”

“Many church leaders worried about the themes of chivalric romances – adultery, bloodshed, and other scandalous topics – so it’s surprising to see a preacher dropping such “adult content” into a sermon,”said James Wade.

For the first time, the researchers have identified the great late-medieval writer Alexander Neckam (1157-1217) as the most likely author of the Humiliamini sermon. The 800-year-old document is part of MS 255, a Peterhouse Cambridge collection of medieval sermons.

Discoveries made 130 years apart

In 1896, M. R. James was looking through Latin sermons from Peterhouse’s library in Cambridge when he was surprised to find passages written in English. He consulted another Cambridge scholar, Israel Gollancz, and together they announced that these were verses from a lost 12th-century romantic poem which they called the Song of Wade. M. R. James promised further comment but this never came.

Nearly 130 years passed with no new evidence coming to light. Several scholars have attempted to work out the meaning of the sermon’s Wade quotation and speculated on what the full legend might have been like.

“Lots of very smart people have torn their hair out over the spelling, punctuation, literal translation, meaning, and context of a few lines of text,” said James Wade.

James Wade and Seb Falk argue that three words have been misread by scholars, because of misleading errors made by a scribe who transcribed the sermon. Most problematically, the letters ‘y’ and ‘w’ became muddled. Correcting these and other errors transforms the translated text from:

‘Some are elves and some are adders; some are sprites that dwell by waters: there is no man, but Hildebrand only.’

to:

‘Thus they can say, with Wade: ‘Some are wolves and some are adders; some are sea-snakes that dwell by the water. There is no man at all but Hildebrand.’

Hildebrand was Wade’s supposed father. While some folk-legends and epics refer to Hildebrand as a giant, if the Wade legend was a chivalric romance, as this study argues, Hildebrand was probably understood to be a normal man.

Chaucer and Wade

The Song of Wade was hugely popular throughout the Middle Ages. For several centuries, its central character remained a major romance hero, among other famous knights such as Lancelot and Gawain. Chaucer twice evoked Wade in the middle of this period, in the late 1300s, but these references have baffled generations of Chaucer scholars.

At a crucial moment in Troilus and Criseyde, Pandarus tells the ‘tale of Wade’ to Criseyde after supper. Today’s study argues that the Wade legend served Pandarus because he not only needed to keep Criseyde around late, but also to stir her passions. By showing that Wade was a chivalric romance, Chaucer’s reference makes much more sense.

In ‘The Merchant’s Tale’, Chaucer’s main character, January, a 60-year-old knight, refers to Wade’s boat when arguing that it is better to marry young women than old. The fact that his audience would have understood the reference in the context of chivalric romance, rather than folk tales or epics, is significant, the researchers argue.

“This reveals a characteristically Chaucerian irony at the heart of his allusion to Wade’s boat,” said James Wade.

The sermon

To make sense of the fragment, the researchers gave more attention to the Humiliamini sermon in its entirety than scholars have previously.

“The sermon itself is really interesting,” said Seb Falk. “It’s a creative experiment at a critical moment when preachers were trying to make their sermons more accessible and captivating.”

“I once went to a wedding where the vicar, hoping to appeal to an audience who he figured didn’t often go to church, quoted the Black Eyed Peas’ song ‘Where is the Love?’ in an obvious attempt to seem cool. Our medieval preacher was trying something similar to grab attention and sound relevant.”

The sermon offers a lesson in humility, a central concern of medieval theologians, but does so in unusual ways. It focuses on a debased Adam and compares human behaviours to animal traits. It presents powerful men who become like wolves because they plunder what doesn’t belong to them. And it compares the actions of cunning, deceitful and rapacious people to those of adders or water-snakes.

“This sermon still resonates today,” James Wade says. “It warns that it’s us, humans, who pose the biggest threat, not monsters.”

The preacher brings in a second topical reference to underline this point, telling the story of a real-life knight and crusader named Hugh of Gournay, who switched sides four times between England and France. The story doesn’t appear in any other surviving source, but the way the preacher tells it, he must have known his listeners would recognise it.

“It’s a bold image,” said Seb Falk: “the repentant Hugh wrapping a noose around his neck and throwing himself on the mercy of the French king is a powerful and really fresh symbol of chivalric humility.”

The researchers noticed multiple similarities in the arguments and writing style of Alexander Neckam, leading them to believe that he probably wrote the sermon.

But whether Neckam himself or an acolyte, the author must have been familiar with Wade and confident that his intended audience would get the reference.

Seb Falk said: “This sermon demonstrates new scholarship, rhetorical sophistication, and inventiveness, and it has strategic aims. It’s the ideal vehicle for the Wade quotation which served an important purpose.”

Seb Falk is a scholar of medieval history and history of science. James Wade is a scholar of English literature from the Middle Ages forward. Both are Fellows at Girton College, Cambridge.

Extract from the new translation of the sermon referring to Wade:

‘Dear [brothers], as to the fact that he says, ‘humble yourselves’, etc. – it could be considered that humility which is against the mighty hand of God is of a particular kind. For there are three kinds of humility: the humility of guilt; the humility of punishment; and the humility of penance.

Now, by the humility of guilt our first parent [Adam] was so humbled that, although he was made master of the whole world before his sins and ruled over everything that was in the world, after his sin, on the other hand, he could not even defend himself from a worthless worm, that is, from a flea or louse. He who was similar to God before sin, was made dissimilar through sin; since ‘by this poison a rose is sometimes turned into spikenard.’

Thus Adam was, from a human, made as if he was non-human; not only Adam, but almost everyone becomes as if non-humans. Thus they can say, with Wade: ‘Some are wolves and some are adders; Some are sea-snakes that dwell by the water. There is no man at all but Hildebrand.’

Similarly, today some are wolves, such as powerful tyrants, who if they can justly take the things of those subject to them, take them; but if not, [do so] by any means. Some imitate serpents, of which there are three kinds. Others become lions, like the proud ones whom God opposes; enough has been said of pride in the art of preaching. Others are foxes, such as cunning detractors and flatterers who speak with a double heart, who have honey in their mouth but bile in their heart. Others are gluttons like pigs, of whom the prophet says ‘their throats are open graves’; and thus each is judged similarly. Indeed, this humility is bad and perverse.’

Share Button

Is there a healthy way to tan?

Chris and Xand van Tulleken weigh up the pros and cons of being in direct sunshine.

Share Button

Physician associates need new job title, says review

It also recommends PAs and AAs wear standardised clothing and badges to distinguish them from doctors.

Share Button

Why are measles cases rising in the UK?

What are the symptoms of measles and how dangerous is the disease?

Share Button

Premises plea as wellbeing charity told to move

Simply Limitless must leave its base in Kidderminster in weeks after the landlord found new tenants.

Share Button

Fasting twice a week could be a game-changer for type 2 diabetes

Intermittent energy restriction, time-restricted eating and continuous energy restriction can all improve blood sugar levels and body weight in people with obesity and type 2 diabetes, according to a study presented at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, California.

“This study is the first to compare the effects of three different dietary interventions intermittent energy restriction (IER), time-restricted eating (TRE) and continuous energy restriction (CER) in managing type 2 diabetes with obesity,” said Haohao Zhang, Ph.D., chief physician at The First Affiliated Hospital of Zhengzhou University in Zhengzhou, China.

Although researchers identified improved HbA1c levels, and adverse events were similar across the three groups, the IER group showed greater advantages in reducing fasting blood glucose, improving insulin sensitivity, lowering triglycerides, and strengthening adherence to the dietary interventions.

“The research fills a gap in directly comparing 5:2 intermittent energy restriction with a 10-hour time-restricted eating in patients with obesity and type 2 diabetes. The findings provide scientific evidence for clinicians to choose appropriate dietary strategies when treating such patients,” Zhang said.

Zhang and colleagues performed a single-center, randomized, parallel-controlled trial at the First Affiliated Hospital of Zhengzhou University from November 19, 2021 to November 7, 2024.

Ninety patients were randomly assigned in a 1:1:1 ratio to the IER, TRE or CER group, with consistent weekly caloric intake across all groups. A team of nutritionists supervised the 16-week intervention.

Of those enrolled, 63 completed the study. There were 18 females and 45 males, with an average age of 36.8 years, a mean diabetes duration of 1.5 years, a baseline BMI of 31.7 kg/m², and an HbA1c of 7.42%.

At the end of the study, there were no significant differences in HbA1c reduction and weight loss between the IER, TRE and CER groups. However, the absolute decrease in HbA1c and body weight was greatest in the IER group.

Compared to TRE and CER, IER significantly reduced fasting blood glucose and triglycerides and increased the Matsuda index, a measure of whole-body insulin sensitivity. Uric acid and liver enzyme levels exhibited no statistically significant changes from baseline in any study group.

Two patients in the IER group and the TRE group, and three patients in the CER group, experienced mild hypoglycemia.

The IER group had the highest adherence rate (85%), followed by the CER group at 84% and the TRE group at 78%. Both the IER and CER groups showed statistically significant differences compared with the TRE group.

Zhang said these findings highlight the feasibility and effectiveness of dietary interventions for people who have obesity and type 2 diabetes.

Share Button

Semaglutide melts fat—but may quietly strip away your strength

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help prevent muscle loss in these patients, according to a small study presented at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.

Losing muscle (or lean mass) is a common side effect of weight loss in adults with obesity and may negatively affect metabolism and bone health. This is because muscle helps control blood sugar after meals and plays an important role in keeping bones strong, according to study lead researcher Melanie Haines, M.D., of Massachusetts General Hospital and Harvard Medical School in Boston, Mass.

Approximately 40% of the weight lost from taking semaglutide — a type of weight-loss medication known as a GLP-1 — comes from lean mass, including muscle. It is not yet known who is at highest risk for muscle loss or how it affects blood sugar levels, Haines said.

The researchers studied 40 adults with obesity for three months. Of these patients, 23 were prescribed semaglutide, while 17 followed a diet and lifestyle program for weight loss called Healthy Habits for Life (HHL). The researchers evaluated how their muscle mass changed.

Study participants who were prescribed semaglutide lost more weight than those who participated in the diet and lifestyle program, but the percent of weight loss that was lean mass was similar between the two groups.

After accounting for weight loss, the researchers found that in the semaglutide group, being older, female or eating less protein was linked to greater muscle loss. Also in this group, losing more muscle was linked to less improvement in blood sugar (HbA1c levels).

“Older adults and women may be more likely to lose muscle on semaglutide, but eating more protein may help protect against this,” Haines said. “Losing too much muscle may reduce the benefits of semaglutide on blood sugar control. This means preserving muscle during weight loss with semaglutide may be important to reduce insulin resistance and prevent frailty in people with obesity.”

Haines said that more studies are needed to find the best way to lose fat but keep muscle when using GLP-1 medications.

Share Button

Weight-loss wonder drug Mounjaro/Zepbound shrinks breast cancer tumors

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study presented at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, California.

“Obesity is a significant risk factor for breast cancer, and while it is very preliminary data, our studies in mice suggest that these new anti-obesity drugs may be a way to reduce obesity-associated breast cancer risk or improve outcomes,” said study author Amanda Kucinskas, B.S., a Ph.D. candidate in the labs of Drs. Erin Giles and Kanakadurga Singer at the University of Michigan in Ann Arbor, Mich.

Existing research has shown that having obesity can lead to worse breast cancer outcomes compared to those who do not have obesity, and weight loss can improve outcomes. However, there are many challenges with traditional weight loss methods.

Kucinskas and colleagues leveraged tirzepatide, one of a new class of effective anti-obesity medications that target GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. The researchers sought to learn whether or not tirzepatide would reduce obesity-associated breast cancer growth.

This mouse study included 16 mice. The 9-week-old C57BL/6 mice were fed a 40% high-fat diet and housed in a warm environment to induce obesity. At 32 weeks of age, the mice with obesity were randomly assigned injections of tirzepatide or a placebo every other day for 16 weeks. Tumor volumes were measured twice weekly.

The researchers found that the anti-obesity drug reduced body weight and body fat by approximately 20% in mice, similar to the amount of weight loss achieved by women on this drug. They found this was primarily due to a loss of adipose mass, with a reduction in adipose depot weights compared to controls.

The anti-obesity drug also reduced tumor volume compared to the controls. At the end of the study, the researchers found that tumor volume was significantly correlated with body weight, total adipose mass and the amount of fat stored in the liver.

“While these are very preliminary results, they suggest that this new anti-obesity drug may also have a beneficial impact on breast cancer outcomes,” Kucinskas said.

Ongoing studies are underway in collaboration with Dr. Steve Hursting’s lab at the University of North Carolina at Chapel Hill to separate the weight loss from the tumor-specific effects of tirzepatide.

Share Button

Biggest human imaging study scans 100,000th person

UK Biobank scientists say the human body can be studied in greater detail than ever thanks to people like Steve.

Share Button

One shot, seven days: Long-acting levodopa gel tackles Parkinson’s tremors

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson’s disease, potentially replacing the need for multiple daily tablets.

Scientists from the University of South Australia (UniSA) have developed a long-acting injectable formulation that delivers a steady dose of levodopa and carbidopa – two key medications for Parkinson’s – over an entire week.

Their findings have been reported in the journal Drug Delivery and Translational Research.

The biodegradable formulation is injected under the skin or into muscle tissue, where it gradually releases the medication over seven days.

Parkinson’s disease is the second most common neurological disorder, affecting more than 8.5 million people worldwide. Currently there is no cure and the symptoms – tremors, rigidity and slow movement – are managed with oral medications that must be taken several times a day.

The frequent dosing is a burden, especially for elderly patients or those with swallowing difficulties, leading to inconsistent medication levels, more side effects, and reduced effectiveness.

Lead researcher Professor Sanjay Garg, from UniSA’s Centre for Pharmaceutical Innovation, says the newly developed injectable could significantly improve treatment outcomes and patient adherence.

“Our goal was to create a formulation that simplifies treatment, improves patient compliance, and maintains consistent therapeutic levels of medication. This weekly injection could be a game-changer for Parkinson’s care,” Prof Garg says.

“Levodopa is the gold-standard therapy for Parkinson’s, but its short life span means it must be taken several times a day.”

UniSA PhD student Deepa Nakmode says the in-situ implant is designed to release both levodopa and carbidopa steadily over one week, maintaining consistent plasma levels and reducing the risks associated with fluctuating drug concentrations.

“After years of focused research, it’s incredibly rewarding to see our innovation in long-acting injectables for Parkinson’s disease reach this stage. Our invention has now been filed for an Australian patent,” Nakmode says.

The injectable gel combines an FDA-approved biodegradable polymer PLGA with Eudragit L-100, a pH-sensitive polymer, to achieve a controlled and sustained drug release.

Extensive lab tests confirmed the system’s effectiveness and safety:

  • More than 90% of the levodopa dose and more than 81% of the carbidopa dose was released over seven days.
  • The implant degraded by over 80% within a week and showed no significant toxicity in cell viability tests.
  • The formulation can be easily administered through a fine 22-gauge needle, minimising discomfort and eliminating the need for surgical implant.

“The implications of this research are profound,” Prof Garg says. “By reducing the frequency of dosing from multiple times a day to a weekly injection is a major step forward in Parkinson’s therapy. We’re not just improving how the drug is delivered; we’re improving patients’ lives.”

Prof Garg says the technology could also be adapted for other chronic conditions such as cancer, diabetes, neurodegenerative disorders, pain management, and chronic infections that require long-term drug delivery.

The system can be tuned to release drugs over a period ranging from a few days to several weeks depending on therapeutic needs.

UniSA scientists hope to start clinical trials in the near future and are exploring commercialisation opportunities.

Share Button